PRKAG1

PRKAG1 Full Name

protein kinase, AMP-activated, gamma 1 non-catalytic subunit

PRKAG1 Introduction

PRKAG1 (protein kinase AMP‑activated non‑catalytic subunit gamma 1) encodes the γ1 regulatory subunit of the AMP‑activated protein kinase (AMPK), a master energy sensor that maintains cellular energy homeostasis. The gene is located on human chromosome 12q13.12 and produces a protein of approximately 331 amino acids with a molecular weight of about 37 kDa. PRKAG1 is ubiquitously expressed in all human tissues, with highest levels in the heart, skeletal muscle, liver, and brain. AMPK is a heterotrimeric complex composed of a catalytic α subunit (α1 or α2, encoded by PRKAA1/PRKAA2), a scaffolding β subunit (β1 or β2, encoded by PRKAB1/PRKAB2), and a regulatory γ subunit (γ1, γ2, or γ3, encoded by PRKAG1, PRKAG2, PRKAG3). The γ subunit directly binds adenyl nucleotides (AMP, ADP, and ATP), enabling the complex to sense cellular energy status. Upon binding of AMP or ADP, the γ subunit induces a conformational change that promotes phosphorylation and activation of the α subunit, leading to a switch from anabolic to catabolic pathways. PRKAG1 is the most widely expressed γ isoform and is essential for basal energy sensing in most cell types.

Figure 1. Strcuture of PRKAG1.

Role in AMPK Activation and Energy Sensing
PRKAG1 functions as the energy‑sensing module of the AMPK complex. Under normal conditions with high ATP, ATP occupies the nucleotide‑binding sites, and AMPK remains largely inactive. When cellular energy falls (e.g., during exercise, ischemia, fasting, or hypoxia), the ATP concentration decreases while AMP and ADP rise. AMP and ADP bind to PRKAG1 with higher affinity, displacing ATP. This binding induces a conformational change that (i) promotes phosphorylation of Thr172 on the α subunit by upstream kinases (LKB1 or CaMKKβ), (ii) inhibits dephosphorylation of Thr172 by protein phosphatases, and (iii) directly allosterically activates the kinase (up to 10‑fold). The net result is a rapid and robust increase in AMPK activity. Because PRKAG1 is the predominant γ isoform in most tissues, it underpins the acute metabolic response to energy stress. In contrast, PRKAG2 is enriched in the heart, and PRKAG3 is predominantly expressed in skeletal muscle, providing tissue‑specific nuances in AMPK regulation.

Clinical Significance and Disease Associations
Unlike PRKAG2, where mutations cause a cardiac syndrome (Wolff‑Parkinson‑White syndrome, hypertrophic cardiomyopathy, and conduction defects), mutations in PRKAG1 are extremely rare and have not been definitively linked to a specific monogenic disorder. However, genome‑wide association studies (GWAS) have implicated PRKAG1 variants in several common conditions, including type 2 diabetes, fasting glucose levels, and blood pressure regulation. One intronic variant (rs1799114) has been associated with altered risk of coronary artery disease in some populations. Loss‑of‑function mutations in PRKAG1 may contribute to metabolic syndrome, but functional validation is lacking. In cancer, PRKAG1 expression is often reduced in tumors, consistent with a tumor suppressor role for AMPK; however, some cancers upregulate PRKAG1 to adapt to metabolic stress. PRKAG1 has also been studied as a potential biomarker for metabolic health and response to metformin. Unlike the severe cardiomyopathy associated with PRKAG2 mutations, PRKAG1 defects are expected to cause more subtle metabolic phenotypes.

Alternate Names for PRKAG1

PRKAG1; protein kinase, AMP-activated, gamma 1 non-catalytic subunit; AMPKG; 5-AMP-activated protein kinase subunit gamma-1; AMPK gamma1; AMPK gamma-1 chain; 5-AMP-activated protein kinase, gamma-1 subunit;